- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01064479
Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
A Randomized, Placebo-Controlled, Phase 2 Study of Docetaxel and Cisplatin/Carboplatin With or Without Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Study Overview
Status
Conditions
- Metastatic Squamous Cell Carcinoma of the Hypopharynx
- Metastatic Squamous Cell Carcinoma of the Larynx
- Metastatic Squamous Cell Carcinoma of the Oral Cavity
- Metastatic Squamous Cell Carcinoma of the Oropharynx
- Recurrent Hypopharyngeal Squamous Cell Carcinoma
- Recurrent Laryngeal Squamous Cell Carcinoma
- Recurrent Oral Cavity Squamous Cell Carcinoma
- Recurrent Oropharyngeal Squamous Cell Carcinoma
- Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7
- Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7
- Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
- Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7
- Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7
- Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7
- Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
- Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7
- Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7
- Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7
- Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
- Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
- Stage IVC Hypopharyngeal Squamous Cell Carcinoma AJCC v7
- Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7
- Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
- Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7
Detailed Description
PRIMARY OBJECTIVES:
I. Assess the efficacy of adding erlotinib hydrochloride (erlotinib) to chemotherapy to improve progression free survival in patients with metastatic or recurrent squamous cell carcinoma of the head and neck.
SECONDARY OBJECTIVES:
I. Evaluate overall survival, response rate, disease control rate, and duration of response by treatment with or without erlotinib.
II. Evaluate quality of life (patient reported outcomes) by treatment with or without erlotinib.
III. Evaluate the safety profile of erlotinib in combination with chemotherapy. IV. Correlate the occurrence of erlotinib-induced rash with outcomes. V. To evaluate the steady-state pharmacokinetics of erlotinib. VI. To explore the prognostic and predictive value of epidermal growth factor receptor related biomarkers and other biomarkers, including blood and tissue proteomic and blood and tissue genomic markers, that may be associated with clinical outcomes.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive docetaxel intravenously (IV) over 1 hour and cisplatin IV over 2 hours or carboplatin IV over 2 hours on day 1, and erlotinib hydrochloride orally (PO) daily on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression and unacceptable toxicity. Patients achieving complete response, partial response, or stable disease may continue erlotinib hydrochloride treatment.
ARM B: Patients receive docetaxel and cisplatin or carboplatin as in Arm I and placebo PO daily on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression and unacceptable toxicity. Patients achieving complete response, partial response, or stable disease may continue placebo treatment.
After completion of study treatment, patients are followed up at 30 days.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- M D Anderson Cancer Center
-
Houston, Texas, United States, 77094
- MD Anderson Regional Care Center-Katy
-
Nassau Bay, Texas, United States, 77058
- MD Anderson Regional Care Center-Bay Area
-
Sugar Land, Texas, United States, 77478
- MD Anderson Regional Care Center-Sugar Land
-
The Woodlands, Texas, United States, 77384
- MD Anderson Regional Care Center-The Woodlands
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically confirmed metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN) of the oral cavity, oropharynx, hypopharynx or larynx; metastatic or recurrent lesions of the nasopharynx and sinus are excluded
- Radiologically measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 20 mm with conventional techniques or as >= 10 mm with spiral computed tomography (CT) scan; measurable lymph nodes are required to be >= 15 mm in size (short axis diameter)
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) =< 2
- Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
- Platelet count >= 100 x 10^9/L
- Total bilirubin =< upper limit of normal (ULN) (excluding Gilbert's disease)
- Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 1.5 x ULN
- Alkaline phosphatase =< 2.5 x ULN
- Serum creatinine =< 1.5 x ULN
- Patients with reproductive potential (e.g., females menopausal for less than 1 year and not surgically sterilized) must practice effective contraceptive measures for the duration of study drug therapy and for at least 30 days after completion of study drug therapy; female patients of childbearing potential must provide a negative pregnancy test (serum or urine) =< 14 days prior to treatment initiation
- Written informed consent to participate in the study according to the investigational review board (IRB) or independent ethics committee (IEC)
Exclusion Criteria:
- Histology other than squamous cell carcinoma
- Primary sites other than oral cavity, oropharynx, hypopharynx, and larynx
- Prior palliative chemotherapy for metastatic or recurrent disease
- Prior biological therapy for metastatic or recurrent disease within 3 weeks prior to randomization
- Patients with known, untreated brain metastases; patients with treated (irradiated or resected) brain metastases are eligible if treatment was completed more than 28 days prior to study entry and if clinical neurologic function is stable
- Pre-existing peripheral neuropathy >= grade 2
- History of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug (e.g., Crohn's disease, ulcerative colitis); patients requiring feeding tubes are permitted
- Other active malignancies requiring chemotherapy treatment within 2 years prior to randomization, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical or breast cancer or superficial, resected melanoma
- Serious underlying medical condition which would impair the ability of the patient to receive protocol treatment, in the opinion of the treating physician
- History of allergic reactions to compounds of similar chemical composition to the study drugs (docetaxel, cisplatin, carboplatin, erlotinib or their excipients), or other drugs formulated with polysorbate 80
- Any concurrent anti-cancer therapy, excluding hormonal therapy for prostate or breast cancer
- Dementia or significantly altered mental status that would prohibit the understanding and giving of informed consent
- Women who are pregnant or breast-feeding and women or men not practicing effective birth control
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A (combination chemotherapy and erlotinib hydrochloride)
Patients receive docetaxel IV over 1 hour and cisplatin IV over 2 hours or carboplatin IV over 2 hours on day 1 and erlotinib hydrochloride PO daily on days 1-21.
Treatment repeats every 21 days for up to 6 courses in the absence of disease progression and unacceptable toxicity.
Patients achieving complete response, partial response, or stable disease may continue erlotinib hydrochloride treatment.
|
Given PO
Other Names:
Given IV
Other Names:
Ancillary studies
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Optional correlative studies
Optional correlative studies
|
Active Comparator: Arm B (combination chemotherapy and placebo)
Patients receive docetaxel and cisplatin or carboplatin as in Arm I and placebo PO daily on days 1-21.
Treatment repeats every 21 days for up to 6 courses in the absence of disease progression and unacceptable toxicity.
Patients achieving complete response, partial response, or stable disease may continue placebo treatment.
|
Given IV
Other Names:
Ancillary studies
Other Names:
Given PO
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Optional correlative studies
Optional correlative studies
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival (PFS)
Time Frame: 5 years
|
Kaplan-Meier methods will be used to summarize PFS.
In the primary analysis, differences in PFS in Arm A versus Arm B will be tested using a stratified log-rank test with a two-sided alpha of 0.10.
Hazard ratios for PFS will be presented using point estimates and 95% confidence intervals.
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival (OS)
Time Frame: 5 years
|
Kaplan-Meier methods will be used to summarize OS.
Hazard ratios for OS will be presented using point estimates and 95% confidence intervals.
|
5 years
|
Number of Participants With Tumor Response (Complete Response [CR] + Partial Response [PR])
Time Frame: 5 years
|
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions
|
5 years
|
Disease Control (CR + PR + Stable Disease [SD])
Time Frame: 5 years
|
Complete Response (CR) + Partial Response (PR) + Stable disease
|
5 years
|
Rash Rates
Time Frame: 5 years
|
Participants with a Rash of at least grade 2 within cycle 1.
|
5 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Xiuning Le, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Head and Neck Neoplasms
- Neoplasms, Squamous Cell
- Carcinoma
- Recurrence
- Carcinoma, Squamous Cell
- Squamous Cell Carcinoma of Head and Neck
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Protein Kinase Inhibitors
- Docetaxel
- Carboplatin
- Erlotinib Hydrochloride
- Cisplatin
Other Study ID Numbers
- 2009-0395 (Other Identifier: M D Anderson Cancer Center)
- NCI-2011-03782 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Squamous Cell Carcinoma of the Hypopharynx
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Head and Neck Squamous Cell Carcinoma | Metastatic Squamous Cell Carcinoma of the Hypopharynx | Metastatic Squamous Cell Carcinoma of the Larynx | Metastatic Squamous Cell Carcinoma of the Oral Cavity | Metastatic Squamous Cell Carcinoma of the Oropharynx | Recurrent Hypopharyngeal... and other conditionsUnited States
-
Kyunghee Burkitt, DO, PhDNot yet recruitingSquamous Cell Carcinoma of the Larynx | Squamous Cell Carcinoma of the Oral Cavity | HPV-Related Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Oropharynx | Squamous Cell Carcinoma of the HypopharynxUnited States
-
University of Erlangen-Nürnberg Medical SchoolRecruitingSquamous Cell Carcinoma of the Larynx | Squamous Cell Carcinoma of the Oral Cavity | Squamous Cell Carcinoma of the Oropharynx | Squamous Cell Carcinoma of the HypopharynxGermany
-
Arbeitsgemeinschaft medikamentoese TumortherapieCompletedSquamous Cell Carcinoma of the Hypopharynx Stage III | Squamous Cell Carcinoma of the Hypopharynx Stage IV | Squamous Cell Carcinoma of the Larynx Stage III | Squamous Cell Carcinoma of the Larynx Stage IV | Squamous Cell Carcinoma of the Oropharynx Stage III | Squamous Cell Carcinoma of the... and other conditionsAustria
-
Arbeitsgemeinschaft medikamentoese TumortherapieMedical University of GrazTerminatedLocally Advanced Malignant Neoplasm | Squamous Cell Carcinoma of the Hypopharynx Stage III | Squamous Cell Carcinoma of the Hypopharynx Stage IV | Squamous Cell Carcinoma of the Oral Cavity Stage III | Squamous Cell Carcinoma of the Oral Cavity Stage IV | Laryngeal Squamous Cell Carcinoma Stage... and other conditionsAustria
-
H. Lee Moffitt Cancer Center and Research InstituteBristol-Myers Squibb; Eli Lilly and Company; James and Esther King Biomedical...Active, not recruitingHead and Neck Squamous Cell Carcinoma | Head and Neck Carcinoma | Squamous Cell Carcinoma of the Larynx | Squamous Cell Carcinoma of the Oral Cavity | Squamous Cell Cancer | Squamous Cell Carcinoma of the Oropharynx | Squamous Cell Carcinoma of the Hypopharynx | Squamous Cell Carcinoma of the Paranasal...United States
-
National Cancer Institute (NCI)TerminatedStage III Squamous Cell Carcinoma of the Hypopharynx | Stage III Squamous Cell Carcinoma of the Larynx | Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage III Squamous Cell Carcinoma of the Oropharynx | Stage IV Squamous Cell Carcinoma of the Hypopharynx | Stage IV Squamous... and other conditionsUnited States
-
Terrence JonesNestléCompletedLaryngeal Squamous Cell Carcinoma | Squamous Cell Carcinoma of Oropharynx | Squamous Cell Carcinoma of Mouth | Squamous Cell Carcinoma of the HypopharynxUnited Kingdom
-
National Cancer Institute (NCI)CompletedMetastatic Squamous Neck Cancer With Occult Primary | Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedStage IV Squamous Cell Carcinoma of the Hypopharynx | Stage IV Squamous Cell Carcinoma of the Larynx | Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage IV Squamous Cell Carcinoma of the OropharynxUnited States
Clinical Trials on Erlotinib Hydrochloride
-
AVEO Pharmaceuticals, Inc.Biodesix, Inc.TerminatedNon-small Cell Lung CancerKorea, Republic of, United States, Australia, Taiwan, Singapore, Hong Kong, Italy
-
M.D. Anderson Cancer CenterCompletedAdvanced CancersUnited States
-
University of ChicagoNational Cancer Institute (NCI)CompletedMalignant Peritoneal MesotheliomaUnited States
-
European Organisation for Research and Treatment...CompletedOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity CancerFrance, Spain, Netherlands, Australia, United Kingdom, Italy, Portugal, Austria
-
University of California, DavisNational Cancer Institute (NCI); Novartis PharmaceuticalsCompletedRecurrent Non-small Cell Lung CancerUnited States
-
Merck Sharp & Dohme LLCCompleted
-
National Cancer Institute (NCI)CompletedCervical Squamous Cell Carcinoma | Recurrent Cervical CancerUnited States
-
The Cleveland ClinicUnknownBrain and Central Nervous System TumorsUnited States
-
Fox Chase Cancer CenterMillennium Pharmaceuticals, Inc.TerminatedNon-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer RecurrentUnited States
-
National Cancer Institute (NCI)CompletedStage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung CancerUnited States